Literature DB >> 33977090

Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field.

Gang Xu1, Bao Jin1, Xiaomeng Xian1, Huayu Yang1, Haitao Zhao1, Shunda Du1, Masatoshi Makuuchi2, Timothy M Pawlik3, Yilei Mao1.   

Abstract

INTRODUCTION: Over the past 4 decades, the management of hepatocellular carcinoma (HCC) has changed dramatically. The publications that have had the most significant impact on HCC management have not been quantitatively analyzed. In this article, we analyzed the 100 most influential articles over the past 4 decades using bibliometric citation analysis to characterize the evolution in HCC treatment.
METHODS: The top-cited publications were identified and analyzed from the Clarivate Analytics Web of Science Core Collection database.
RESULTS: The 100 most cited articles were identified with an average of 738 citations (range: 349-6,799). There was an increase in the number of influential articles in the late 1990s, which was paralleled by an increase in reports focused on locoregional treatment of HCC. Most top 100 articles came from the USA (n = 35), followed by Italy (n = 28), mainland China (n = 26), and Japan (n = 24). The surgical management was the most studied topic (n = 33). The Annals of Surgery published the highest number of papers (n = 26) with 13,978 citations. While other 3 topics (surgical management, locoregional treatment, and outcome prediction) declined among publications beginning in the 2000s, there was an emergence of highly cited papers on targeted drugs and immune checkpoint inhibitors with a concomitant increase in the number of publications on systemic therapy.
CONCLUSIONS: Based on bibliometric analysis of the literature over the last 40 years, a comprehensive analysis of the most historically significant HCC management articles highlighted the key contributions made to the evolution and advancement of this specialist field. The data should provide clinicians and researchers insight into future directions relative to the advancement of HCC management.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Bibliometric analysis; Hepatocellular carcinoma; Management; Treatment

Year:  2021        PMID: 33977090      PMCID: PMC8077437          DOI: 10.1159/000513412

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  70 in total

1.  Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.

Authors:  J N Vauthey; A Chaoui; K A Do; M M Bilimoria; M J Fenstermacher; C Charnsangavej; M Hicks; G Alsfasser; G Lauwers; I F Hawkins; J Caridi
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

2.  OPTN/SRTR 2013 Annual Data Report: liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2015-01       Impact factor: 8.086

3.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

Review 4.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 5.  Image-guided ablation of primary liver and renal tumours.

Authors:  David J Breen; Riccardo Lencioni
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

6.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Authors:  Andrew X Zhu; Masatoshi Kudo; Eric Assenat; Stéphane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T P Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B Sellami; Li-Tzong Chen
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

7.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

8.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

View more
  4 in total

1.  Cisplatin and oleanolic acid Co-loaded pH-sensitive CaCO3 nanoparticles for synergistic chemotherapy.

Authors:  Muhammad Waseem Khan; Chenming Zou; Said Hassan; Fakhar Ud Din; Mahaman Yacoubou Abdoul Razak; Asif Nawaz; Abdul Wahab; Sudhair Abbas Bangash
Journal:  RSC Adv       Date:  2022-05-16       Impact factor: 4.036

2.  Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field.

Authors:  Siyuan Chen; Yu Qiao; Juan Chen; Yanan Li; Jianlian Xie; Pengfei Cui; Ziwei Huang; Di Huang; Yiming Gao; Yi Hu; Zhefeng Liu
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 3.  Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020.

Authors:  Zhen He; Lei Dai; Yuyue Zuo; Yu Chen; Hongjie Wang; Hesong Zeng
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

Review 4.  Frontiers of ferroptosis research: An analysis from the top 100 most influential articles in the field.

Authors:  Kunming Cheng; Qiang Guo; Zefeng Shen; Weiguang Yang; Yan Zhou; Zaijie Sun; Xiuhua Yao; Haiyang Wu
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.